艾拉莫德治疗类风湿性关节炎临床疗效观察

目的：观察艾拉莫德治疗类风湿性关节炎的临床疗效。方法依治疗药物不同将60例确诊为类风湿性关节炎患者分为两组，对照组30例，给予甲氨蝶呤口服；治疗组30例，给予艾拉莫德口服，两组患者观察治疗12周。对比治疗前后两组患者的临床疗效，并分别评定关节疼痛指数、肿胀指数、晨僵及血沉、C-反应蛋白的变化情况。结果治疗组总有效率（93.33%）明显优于对照组总有效率（80.00%），差异具有统计学意义（P〈0.05）；两组患者治疗后的主要症状、体征及血液学检查均有改善，与治疗前比较有显著性差异（P〈0.05）；治疗组治疗后的主要症状、体征及血液学检查与对照组治疗后比较，差异具有统计学意义（P〈0.05）。结论艾拉莫德治疗类风湿性关节炎有较好的临床疗效，且不良反应发生率低，值得在临床上推广。

Therapeutic effectiveness of iguratimod in patients with rheumatoid arthritis

Objective To observe the efficacy and safety of iguratimod in the treatment of rheumatoid arthritis （RA）. Methods A total of 60 cases of RA patients were divided into two groups, the treatment group （n=30） were given with iguratimod;the control group（n=30） was treated with methotrexate. Each group of patients with treatment was follow-up to the end of the 12th week. The total curative effect, observation efficacy, joint pain index, swelling index, morning stiffness, erythrocyte sedimentation rate and C-reactive protein were used at pre-treatment and treatment at the end of 12 weeks. Results Twelve weeks after treatment, the total curative effect, joint pain index, swelling index, morning stiffness, erythrocyte sedimentation rate and C-reactive protein in the treatment group showed improvement,and statis-tical difference was observed when compared with pre-treatment （P〈0.05）. Compared with the control group, the total curative effect, joint pain index, swelling index, morning stiffness, erythrocyte sedimentation rate and C-reactive protein in the treatment group showed significantly improvement （P〈0.05）. Conclusion The effect of treating RA with igurati-mod is safe and valuable to extend in clinic.